News

ACCESS BELAB1407 AND BELAB2122 WORLD LEADING DRUG DISCOVERY PLATFORMS

Hamburg, Germany, 22 February 2023:

To help our academic partners realise their drug discovery ideas, beLAB1407 offers preferred access to Evotec´s world leading drug discovery platforms and expertise.

From HTS to preclinical drug development, from small molecules to gene therapy, we provide you with all the necessary expertise and experimentation to develop your ideas to the clinic.

Starting in March 2023, in a series of tailor presentations, beLAB1407 would like to invite all our partners to join a special series of 1 hour webinars highlighting some of the key technologies that are available to you via the funding scheme.

From Evotec specialists you will be guided through diverse topics with the opportunity to explore how beLAB1407 can support your drug discovery needs.

Over the course of 2023, the following topics will be presented by Evotec´s experts:

• Hit identification capabilities including HTS and virtual screening
• Generation and optimisation of human antibodies
• Medicinal chemistry optimisation of early-stage hits
• RNA and DNA targeting
• Drugging the undruggable, anti-sense oligonucleotides and protein degraders

This is a great opportunity to hear how beLAB1407 can support you in your ambitions to develop tomorrow´s drugs. We look forward to welcoming you!

EVOTEC’S TRANSLATIONAL BRIDGE beLAB1407 AWARDS PROJECT FROM DUNDEE UNIVERSITY

Hamburg, Germany, 1 August 2022:

• PROJECT ORIGINATES FROM DR IGNACIO MORAGA’S LAB AND FOCUSES ON INFLAMMATORY DISORDERS
• BELAB1407 IS A TRANSLATIONAL BRIDGE COLLABORATION BETWEEN EVOTEC, BRISTOL MYERS SQUIBB AND UK UNIVERSITIES

Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809; NASDAQ: EVO) announced today that after a successful call for proposals, University of Dundee has been awarded its first funding within the beLAB1407 BRIDGE initiative. beLAB1407 is a translational BRIDGE collaboration between Evotec and Bristol Myers Squibb, aiming to accelerate translational research from the UK’s academic life science ecosystem.

EVOTEC ANNOUNCES FIRST FUNDED PROJECTS OF TRANSLATIONAL BRIDGE beLAB1407 IN COLLABORATION WITH BRISTOL MYERS SQUIBB

Hamburg, Germany, 27 October 2021:

• FIRST TWO PROJECTS FROM THE UNIVERSITIES OF BIRMINGHAM AND EDINBURGH SELECTED
• beLAB1407 IS A TRANSLATIONAL BRIDGE COLLABORATION BETWEEN EVOTEC AND BRISTOL MYERS SQUIBB

Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) today announced the first two projects to be developed within beLAB1407, a collaboration between Evotec and Bristol Myers Squibb to accelerate translational research from the UK’s academic life science ecosystem. Only six months after signing the beLAB1407 collaboration agreement in May 2021, the first projects to be developed within this academic BRIDGE collaboration have now been identified.

EVOTEC LAUNCHES “beLAB1407” TO ACCELERATE TRANSLATIONAL RESEARCH FROM THE UK’S ACADEMIC LIFE SCIENCE ECOSYSTEM IN COLLABORATION WITH BRISTOL MYERS SQUIBB

Hamburg, Germany, 06 May 2021:

• beLAB1407 TRANSLATES ACADEMIC INNOVATION FROM LEADING ACADEMIC INSTITUTIONS IN THE UK
• THE COLLABORATION LEVERAGES EVOTEC’S UNIQUE MULTIMODALITY PLATFORM TO VALIDATE FIRST-IN-CLASS THERAPEUTIC CONCEPTS FROM THE UNIVERSITIES OF BIRMINGHAM, EDINBURGH, NOTTINGHAM, AND DUNDEE
• BRISTOL MYERS SQUIBB JOINS beLAB1407 AS A BIOPHARMA COLLABORATOR

Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) announced today that the Company, together with Bristol-Myers Squibb Company (NYSE: BMY), has launched beLAB1407, a new $ 20 m academic BRIDGE to identify and advance novel and breakthrough drug discovery opportunities across therapeutic areas from the UK’s top-tier academic institutions. Through a unique combination of Evotec’s drug discovery and development platforms and early-stage therapeutic concepts from the Universities of Birmingham, Edinburgh, Nottingham, and Dundee, beLAB1407 offers a unique route to the advancement of first-in-class therapeutics and the creation of spin-out companies.

EVOTEC LAUNCHES “beLAB1407” TO ACCELERATE TRANSLATIONAL RESEARCH FROM THE UK’S ACADEMIC LIFE SCIENCE ECOSYSTEM IN COLLABORATION WITH BRISTOL MYERS SQUIBB

Hamburg, Germany, 06 May 2021:

• beLAB1407 TRANSLATES ACADEMIC INNOVATION FROM LEADING ACADEMIC INSTITUTIONS IN THE UK
• THE COLLABORATION LEVERAGES EVOTEC’S UNIQUE MULTIMODALITY PLATFORM TO VALIDATE FIRST-IN-CLASS THERAPEUTIC CONCEPTS FROM THE UNIVERSITIES OF BIRMINGHAM, EDINBURGH, NOTTINGHAM, AND DUNDEE
• BRISTOL MYERS SQUIBB JOINS beLAB1407 AS A BIOPHARMA COLLABORATOR

Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) announced today that the Company, together with Bristol-Myers Squibb Company (NYSE: BMY), has launched beLAB1407, a new $ 20 m academic BRIDGE to identify and advance novel and breakthrough drug discovery opportunities across therapeutic areas from the UK’s top-tier academic institutions. Through a unique combination of Evotec’s drug discovery and development platforms and early-stage therapeutic concepts from the Universities of Birmingham, Edinburgh, Nottingham, and Dundee, beLAB1407 offers a unique route to the advancement of first-in-class therapeutics and the creation of spin-out companies.